BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

New evidence hints that statins may protect a wider range of people with type 2 diabetes than previously assumed. A major ...

Findings of reduced risks for mortality and major CVD suggest consideration of statins in all adults with type 2 diabetes, even in those with low short-term predicted CVD risk.

Individuals who achieved a BMI of less than 25 kg/m2 in the SURMOUNT trials of tirzepatide also experienced significant ...

The Adriatic diet represents a regional Mediterranean dietary pattern rich in olive oil, plant foods, and fish that supports ...

(HealthDay News) — Among persons at high cardiovascular risk, there is low- to moderate-certainty evidence that reducing or modifying saturated fat intake can reduce mortality and major cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . In the SELECT trial, there were no linear trends between weight loss with semaglutide and reduction in CV risk.

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.

Vigorous exercise places greater demand on the cardiovascular system, encouraging adaptations in the heart and lungs, Holmer ...